Short answer
DiaMedica Therapeutics Inc. (DMAC) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
DiaMedica Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full condensed financial results available in Exhibit 99.1, relevant for assessing liquidity and operating performance
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $10.1M, up from $7.7M, with R&D expense rising to $8.2M from $5.8M
- Cash, equivalents and investments $43.5M, down from $59.9M at December 31, 2025, supporting planned operations through 2027
- DM199 reduced systolic blood pressure 29.1 mmHg and diastolic pressure 17.0 mmHg in 15 late-onset preeclampsia patients, both p<0.001
- Early-onset fetal growth restriction cohort enrolled 6 participants at 5 µg/kg, with topline results expected in September
- ReMEDy2 stroke trial surpassed 85% enrollment toward 200 participants, with interim analysis anticipated in early 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other DiaMedica Therapeutics Inc. 8-K filings
Get the next DMAC 8-K as it lands
Follow DMAC for push alerts, or ask the research agent what this filing means.